We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cholera vaccines.
- Authors
Ryan, E T; Calderwood, S B
- Abstract
Cholera causes significant morbidity and mortality worldwide. For travelers, the risk of developing cholera per month of stay in a developing country is approximately 0.001%-0.01%, and cholera may present as traveler's diarrhea. In the United States, only a poorly tolerated, marginally effective, parenterally administered, phenol-inactivated vaccine is available. Outside the United States, 2 additional vaccines are commercially available: an oral killed whole cell-cholera toxin recombinant B subunit vaccine (WC-rBS) and an oral live attenuated Vibrio cholerae vaccine (CVD 103-HgR). These oral vaccines are well tolerated. In field trials, WC-rBS provides 80%-85% protection from cholera caused by V. cholerae serogroup O1 for at least 6 months. In volunteer studies, CVD 103-HgR provides 62%-100% protection against cholera caused by V. cholerae for at least 6 months. No commercially available cholera vaccine protects against disease caused by V. cholerae serogroup O139. New cholera vaccines are being developed.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Vol 31, Issue 2, p561
- ISSN
1058-4838
- Publication type
Journal Article
- DOI
10.1086/313951